Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04965116
Other study ID # 210357
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 25, 2021
Est. completion date November 4, 2022

Study information

Verified date April 2024
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the impact of early initiation (less than one week postpartum) and delayed initiation (4 weeks postpartum) of two types of progestin-only contraceptive pills (POPs) on maternal, breastmilk, and infant outcomes.


Description:

This is a placebo-controlled randomized controlled trial enrolling dyads of birthing people and their newborn infants. We will explore if the type and timing of initiation of pills is acceptable to the user with minimal side effects, impacts the supply or composition of breastmilk, and/or affects infant growth. Birthing people will be randomly assigned to 1 of 3 groups and will be blinded to group assignment: 1. immediate initiation of drospirenone-containing progestin-only pills (d-POPs), 2. immediate initiation of norethindrone-containing progestin-only pills (n-POPs) 3. immediate initiation of a placebo pill for one month followed by d-POPs.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 4, 2022
Est. primary completion date November 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - Desires to use POPs for 3 months - Speak English or Spanish - Had a vaginal or cesarean delivery of a singleton full term (=37 weeks) infant less than 168 hours prior - Intends to breastfeed exclusively for 6 months Exclusion Criteria: - Desire another pregnancy in less than 6 months - Do not intend to exclusively breastfeed - Do not have access to a telephone - Have any medical contraindication to POPs - Have any contraindication to breastfeeding, including maternal illegal drug use, history of augmentation or reduction, infant with major congenital anomaly - Cognitively impaired - Currently incarcerated

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Progestin Only Contraceptive Pills
Daily pill (placebo or active tablet)

Locations

Country Name City State
United States University of California, San Diego La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Diego

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Exclusive Lactation Among Birthing People at 8 Weeks Postpartum. Lactation status will be assessed at 8 weeks postpartum through an email self-reported survey. 8 weeks postpartum
Secondary Proportion of Birthing People Using Progestin-only Pills at 8 Weeks Postpartum Type of contraception being used at 8 weeks postpartum will be assessed through an email self-reported survey. 8 weeks postpartum
Secondary Vaginal Bleeding Number of days of any bleeding and spotting among birthing people in last week will be collected via self-reported email survey. 8 weeks postpartum
Secondary Satisfaction With Assigned POP Overall satisfaction and if birthing people would recommend the POP they were assigned to use to a friend will be ascertained from an email self-report survey. Counts are the number of birthing people who responded "yes". 8 weeks postpartum
Secondary Protein Content of Human Milk Mid-feeding milk samples will be pumped by birthing people and analyzed. 4 weeks postpartum
Secondary Carbohydrate Content of Human Milk Mid-feeding milk samples will be pumped by birthing people and analyzed. 4 weeks postpartum
Secondary Fat Content of Human Milk Mid-feeding milk samples will be pumped by birthing people and analyzed. 4 weeks postpartum
Secondary Perception of Milk Supply Self-reported perception of adequacy of milk supply will be collected with the 20-item Hill and Humenick Lactation Scale among birthing people. Minimum scale score is 20 and maximum is 140, with higher scores representing a more positive perception of breastfeeding. 8 weeks postpartum
Secondary Change in Infant Weight Infant weight in grams will be compared over 4 weeks. Baseline and 4 weeks after delivery
Secondary Change in Infant Height Infant length as measured on a marked board to the nearest millimeter will be compared over 4 weeks. Baseline and 4 weeks after delivery
Secondary Change in Infant Head Circumference The maximum diameter through the infant's glabella and occiput is found and measured with a tape measure and recorded to the nearest millimeter and compared over 4 weeks. Baseline and 4 weeks after delivery
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A